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Abstract
Background: Intercellular adhesion molecule-1 (ICAM-1) is a critical target-docking molecule on
epithelial cells for 90% of human rhinovirus (HRV) serotypes. Two forms of ICAM-1 exist,
membranous (mICAM-1) and soluble (sICAM-1), both expressed by bronchial epithelial cells.
Interferon-gamma (IFN-γ), a crucial Th-1 immuno-regulatory mediator, can modulate mICAM-1
expression; however its simultaneous effects on mICAM-1: sICAM-1 levels and their consequent
outcome on cell infectivity have not been previously explored.
Methods: Primary normal human bronchial epithelial cells were pre-stimulated with IFN-γ (1 ng/
ml for 24 h) and subsequently inoculated with HRV-14 or HRV-1b (TCID50 10 2.5). Epithelial surface
ICAM-1 expression and soluble ICAM-1 release were measured at the protein and gene level by
immunofluorescence and ELISA respectively; mRNA levels were semi-quantified using RT-PCR.
Molecular mechanisms regulating I C A M - 1  i s o f o r m  e x p r e s s i o n  a n d  e f f e c t s  o n  e p i t h e l i a l  c e l l
infectivity were explored.
Results: In IFN-γ-biased cells infected with HRV-14, but not HRV-1b, mICAM-1 expression is
down-regulated, with simultaneous induction of sICAM-1 release. This differential effect on HRV-
14 receptor isoforms appears to be related to a combination of decreased IFN-γ-induced JAK-
STAT signalling and proteolytic receptor cleavage of the membranous form in IFN-γ-biased HRV-
14 infected cells. The observed changes in relative mICAM-1: sICAM-1 expression levels are
associated with reduced HRV-14 viral titres.
Conclusion: These findings support the hypothesis that in epithelial cells conditioned to IFN-γ and
subsequently exposed to HRV-14 infection, differential modulation in the ratio of ICAM-1
receptors prevails in favour of an anti-viral milieu, appearing to limit further target cell viral
attachment and propagation.
Background
Intercellular adhesion molecule-1 (ICAM-1) is a cell sur-
face glycoprotein, which together with its cognate ligand
LFA-1 (CD18/CD11a) recruits and activates immune
effector cells to sites of inflammation. Through separate
domains, ICAM-1 can also serve as a crucial target-dock-
ing molecule on epithelial cells for 90% of human rhino-
virus (HRV) serotypes; recognised to be involved in up to
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65% of "common colds" and associated with exacerba-
tions of chronic airways disease such as asthma and
COPD. In the main, HRV respiratory infections tend to be
normally brief and self-limiting in nature; the precise reg-
ulatory mechanisms for this are not fully understood. The
present work explores some of the underlying processes
focusing on ICAM-1 expression and regulation.
Two distinct forms of ICAM-1 receptor have been identi-
fied, membrane bound (mICAM-1) and soluble (sICAM-
1) [1]; both are expressed by airway epithelial cells (EC).
The present authors previously demonstrated that HRV
selectively manipulates epithelial cell mICAM-1 and
sICAM-1 expression in an inverse fashion to effect airway
epithelial cell infection and thus promote/propagate viral
respiratory episodes [2]. Membrane ICAM-1 expression
can also be modulated by inflammatory cytokines,
already expressed in the local milieu or induced by the
viruses themselves [3-8]. Whilst the ICAM-1 gene appears
to be sensitive to diverse cytokines, the magnitude and
nature of each specific mediator-driven response appears
to be highly dependent on cell type [9,10]. Crucially, the
course of HRV infection can also be manipulated by the
types and time kinetics of inflammatory cytokines in the
immediate cell milieu [11-13]. Of interest, the present
authors have demonstrated that IFN-γ induces down-reg-
ulation of mICAM-1 expression in HRV-14- infected cells
with consequent decrease in viral titres and cell infection
[14]. As this suppressor action contrasts with induction of
same cell receptor by IFN-γ in the absence of infection, it is
unclear whether IFN-γ-induced decrease in infected cell
mICAM-1 levels can solely explain consequence on HRV
infectivity. Indeed the effect of IFN-γ on soluble ICAM-1
isoforms during HRV infection has not been described to
date. This is of interest as IFN-γ is a key anti-viral lym-
phokine in the host immune response against viral infec-
tions. The present authors hypothesise that IFN-γ biased
cells exposed to HRV-14 may selectively modulate own
ICAM-1 receptor levels, promoting a down-regulation of
mICAM-1 expression, whilst inducing sICAM-1 release
into the local milieu. A shift towards the sICAM-1 variant
would favour abrogation or limitation of HRV infection,
and may explain, albeit partly, the self-limiting nature of
rhinovirus infections observed in vivo. In support, sICAM-
1 has been shown to possess anti-viral properties both in
vitro [15] and in vivo [16,17].
To test this hypothesis, in this current study a series of
experiments were designed first, (a) to determine the
influence of IFN-γ alone on bronchial epithelial cell
expression of both mICAM-1 and sICAM-1 forms at the
protein and gene level; and (b) to examine the conse-
quences of IFN-γ cell preconditioning on subsequent HRV
binding and infection. To ensure that the observed effects
of the major group rhinovirus, HRV-14, on ICAM-1
expression are receptor mediated, a minor group rhinovi-
rus (HRV-1b) which utilises a separate low density lipo-
protein receptor, and not ICAM-1, was used as control. As
IFN-γ is known to act via a STAT-1 dependent pathway
[18], the present work next explored the role of this signal
transducer in the regulation of mICAM-1 during HRV
infection. Furthermore, potential pathways of sICAM-1
production, including proteolytic cleavage, were explored
using inhibitors of gene transcription and protein synthe-
sis as well as protease inhibitors.
Methods
Epithelial cell cultures and viral stocks
Commercially available normal human bronchial epithe-
lial cells (NHBE) (three separate sources) were obtained
from Clonetics Corporation Walkersville MD USA. NHBE
cells were cultured in small airway basal medium (SABM)
supplemented with epidermal growth factor (25 ng/ml),
hydrocortisone (0.5 μg/ml), insulin (5 μg/ml), transferrin
(10  μg/ml), epinephrine (0.5 μg/ml), triiodothyronine
(6.5 ng/ml), bovine pituitary extract (52 μg/ml), retinoic
acid (0.1 ng/ml), gentamicin (50 mg/ml), amphotericin B
(50 μg/ml) at 37°C in humidified 5% CO2/air. All rea-
gents were supplied by Clonetics (above). In subsequent
experiments, NHBE cells were seeded in 25 cm2 flasks at a
density of 125 000 cells/flask and utilised when 70–80%
confluent.
The major group rhinovirus seed (HRV-14) was kindly
donated by J. Kent (University of Leicester UK) and the
minor group rhinovirus (HRV-1b) was donated by S.
Johnston (Imperial College, London). A stock solution of
both HRV-14 and HRV-1b rhinoviruses were generated by
infecting confluent monolayers of HeLa Ohio cell line as
described previously [14]. Briefly, confluent monolayers
of Hela cells were inoculated with either HRV-14 or HRV-
1b at a known dilution (102.5TCID50/ml) and incubated
for 90 mins at 34°C in humidified 5% CO2/air. After
which, cells were cultured until cytopathic effect (CPE)
was > 80%. Medium containing virus was centrifuged at
600 g for 10 mins; then viral suspension was stored at -
80°C until use.
Prior to use, viral stocks (HRV-14 and HRV-1b) were puri-
fied using a sucrose gradient. 20 μg/ml RNase A (Sigma,
UK) was added to the viral suspension and incubated at
35°C for 20 mins. 1% sodium sarkosyl (Sigma-Aldrich,
UK) and 2-mercaptoethanol (1 μg/ml) were added to the
RNase treated viral suspension. This was then overlayed
on 1 ml of purification solution (20 mM Tris Acetate, 1 M
NaCl, 30% w/v sucrose) and centrifuged at 200 000 g for
5 h at 16°C. The supernatant was discarded and the result-
ing virus pellet was resuspended in medium and stored at
-80°C until required.Journal of Inflammation 2008, 5:8 http://www.journal-inflammation.com/content/5/1/8
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IFN-γ treatment of NHBE cells
To determine effect of the Th-1 cytokine, IFN-γ, on expres-
sion of ICAM-1 isoforms in airway epithelial cells,
medium was removed from cell cultures containing 70–
80% confluency and replaced with either media contain-
ing IFN-γ (1 ng/ml, R & D Systems, Abingdon UK) or
standard SABM media (controls) for 24 h at 37°C in
humidified 5% CO2/air. Prior studies had demonstrated
stated concentration and time period as optimum for
maximal induction of in mICAM-1 expression (14). All
experiments were set up in triplicate and repeated for each
donor NHBE culture. Media containing IFN-γ and stand-
ard SAGM media were then removed and cell monolayers
washed with PBS.
HRV infection of NHBE cells
To determine whether expression behaviour of ICAM-1
isoforms in HRV-infected airway epithelial cells is influ-
enced by IFN-γ pre-conditioning (i.e. IFN-γ-biased target
cells), parallel cultures of untreated and IFN-γ-treated
NHBE cell monolayers were exposed to SABM media con-
taining HRV-14 (102.5TCID50/ml, previously determined
as the optimum dose, see ref 14), HRV-1b (102.5TCID50/
ml) or virus free media for 90 mins at 34°C, 5% CO2/air.
The cells were then washed 3 times in PBS and standard
SABM medium was replaced on all cell monolayers to sus-
tain cell growth. The gene and protein expressions of
membrane and soluble ICAM-1 forms were measured
simultaneously at 0, 8, 24 and 96 h post infection. 0 h rep-
resents the point immediately after 90 min inoculation
period; subsequent time points (8 to 96 h) are taken from
this 0 h. of viral infection. ICAM-1 is the cellular receptor
for the major group of human rhinoviruses, HRV-14; as
control, another viral strain (minor group rhinovirus
HRV-1b, which utilises a separate low density lipoprotein
receptor) was included to determine whether observa-
tions were receptor mediated. All experiments were set up
in triplicate and repeated for each donor NHBE culture. In
all cultures, cells and supernatants were recovered at 0 h,
8 h, 24 h, and 96 h. for further evaluation; supernatants
were stored at -70°C for soluble ICAM-1 level assays and
viral titre analysis.
sICAM-1 protein ELISA
Soluble ICAM-1 assays were performed with a commer-
cially available ELISA kit (BioSource International, Cali-
fornia USA). The minimum detectable level of human
soluble ICAM-1 (hsICAM-1) was < 0.04 ng/ml. 100 μl of
undiluted cell culture supernatant or standard were uti-
lised in the assay, which was performed in accordance
with the manufacturer's guidelines.
Immunofluoresecence analysis of mICAM-1 protein
Membrane bound ICAM-1 expression and localisation
was evaluated at 0 h, 8 h, 24 h, and 96 h post HRV infec-
tion. At each time point, the cells were collected via
trypsinisation and centrifugation; 6 cytospins for each
experimental condition at each time point were prepared
for immunofluorescence staining; remaining cells were
utilised for RNA extraction, cDNA synthesis and RT-PCR.
Internal controls consisted of unstimulated and unin-
fected cells at each time point to allow comparisons
between controls and IFN-γ treated/infected cells. A cytok-
eratin immunoglobulin IgG-specific monoclonal anti-
body (Sigma-Aldrich, UK) was used to confirm the
epithelial origin of NHBE cell lines used. NHBE cells were
incubated with ICAM-1 monoclonal antibody at a con-
centration of 5 μg/ml, (R1/1.1, IgG Boehringer Ingelheim,
USA) at room temperature for 30 mins. After washing
thoroughly with PBS, a secondary anti-mouse IgG FITC
conjugated antibody (Sigma Aldrich, Dorset, UK) used at
1:500 dilution for 30 minutes at room temperature. The
cells were then washed and mounted using Vectashield®
mounting medium containing DAPI (Vector laboratories,
Peterborough, UK). Slides were viewed under epifloures-
cence with filter set at 450–490 nm for FITC and 340–380
nm for DAPI. Images were obtained using a Leica DC200
digital camera and software (Leica Microsystems, Heer-
brugg, Switzerland). For each experimental condition,
500 cells from five random fields of view were imaged and
analysed for each experimental condition; all slides were
coded prior to analysis and read blind. The data is
expressed as the percentage of positive stained cells ±
S.E.M.
RNA extraction and reverse transcription
Total RNA was extracted from NHBE cells at 0, 8, 24 and
96 h post infection using Trizol (GibcoBRL, Paisley UK)
according to the manufacturer's guidelines; cDNA was
synthesised from 2 μg of RNA. cDNA synthesis was con-
ducted in a reaction mixture containing 20 pmol oligo dt
primer, 5× buffer (50 mM, pH 8.3 75 mM KCl 3 mM
MgCl2), 0.5 mM dNTP mix, 0.5 units RNase inhibitors
and 200 units MMLV reverse transcriptase; the total reac-
tion volume was 20 μl. All cDNA synthesis reagents were
obtained from Clontech (Palo Ato USA). This mixture was
then incubated at 42°C for 1 hr, after which the reverse
transcriptase and DNase were heat inactivated at 94°C for
5 mins. The cDNA was diluted to a final volume of 100 μl
and stored at -80°C for Reverse Transcription Polymerase
chain reaction (RT-PCR).
Detection of m and sICAM-1 gene expression using RT-
PCR
Glyceraldehyde-3-phosphate dehydrogenase (G3PDH)
was used as a control for cDNA synthesis and RT-PCR.
Primers used to detect G3PDH were 5' TGA AGG TCG
GAG TCA GA 3' (sense) and CAT GTG GGC CAT GAG
GTC CAC CAC (antisense). Primers for the detection of
mICAM-1 and sICAM-1 were based on Wakatsuki et alJournal of Inflammation 2008, 5:8 http://www.journal-inflammation.com/content/5/1/8
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(1995) [19]. The sequence of the sense primers used to
detect mICAM-1 and sICAM-1 was 5'CAA GGG GAG GTC
ACC CGC GAG GTG 3' and 5' CAA GGG AGG TCA CCC
GCG AGC C 3' respectively. Both primers were used in
combination with a common antisense primer with the
following sequence 5' TGC AGT GCC CAT TAT GAC TG 3'.
The RT-PCR consisted of 25 pmol primers, 200 μM
dNTPs, 1.5 mM MgCl2, 5 μl 10× PCR buffer and 2.5 U
Amplitaq Gold (Perkin-Elmer, Warrington UK) in a 50 μl
reaction mixture in a thermal cycler (PTC 200 Pielter Ther-
mal cycler) under the following conditions:- 95°C for 12
mins, 94°C for 1 min and 15 secs (denaturation step),
60°C (G3PDH) or 65°C (ICAM-1) for 1 min and 15 secs
(annealing step) and 72°C for 1 min (extension step) for
a total of 30 cycles (G3PDH) or 35 cycles (ICAM-1), after
which a final extension step was performed at 72°C for 10
mins. RT-PCR products were resolved using 3% metaphor
agarose (Flowgen, Litchfield UK) gel in TBE buffer (89
mM Tris, 89 mM boric acid, 2 mM EDTA, Sigma-Aldrich
UK). Gels were visualised using Ethidium Bromide and
UV light, and analysed densitometrically (Model GS-670,
BioRad, Hemel Hempstead, UK) using Molecular Analyst
(version 1.5) (BioRad, UK). Restriction endonucleases
were used to confirm the size of the RT-PCR products.
Membrane bound ICAM-1 RT-PCR products were
digested to give product sizes of 45 base pairs and 57 base
pairs and soluble ICAM-1 RT-PCR products were digested
at the site of the deletion to give 63 bp and 20 bp prod-
ucts. In addition, to confirm the presence of the 19 bp
deletion, RT-PCR amplicons were sequenced using a ABI
PRISM automated sequencer model 310 (Perkin Elmer,
California, USA).
Regulation of ICAM-1 receptors
To enquire at which level, and how, IFN-γ may regulate
expression and release of ICAM-1 isoforms in uninfected
and HRV-infected NHBE cells, a series of different
approaches was adopted. In a first set of experiments two
different pharmacological inhibitors were used.
Inhibition of de novo protein synthesis
IFN-γ-naive NHBE cell cultures were first pre-incubated
for 2 h at 37°C, humidified 5% CO2/air with 10 μg/ml of
cycloheximide (Sigma-Aldrich, Dorset); used for its
known inhibition of protein synthesis [20]. Cells were
then washed and incubated with media containing IFN-γ
(1 ng/ml) or standard SABM for 24 h; after which some
cultures were infected with HRV-14 as described above.
Levels of membranous and soluble ICAM-1 levels were
then determined as above.
Inhibition of gene transcription
In others cultures, actinomycin D (Sigma-Aldrich, Dor-
set), an inhibitor of gene transcription was used to block
the effects of IFN-γ and HRV-14 on ICAM-1 gene tran-
scription. NHBE cells were incubated with actinomycin D
at a concentration of 10 μg/ml (identified as optimum
dose in previous dose- response experiments; data not
shown) for 2 h at 37°C in humidified 5% CO2/air. Cell
monolayers were washed and incubated with IFN-γ condi-
tioned media (1 ng/ml) or standard SABM media. Appro-
priate wells were infected with HRV-14 as above. Levels of
membranous and soluble ICAM-1 levels were then deter-
mined as above.
Role of JAK/STAT-1 pathway in regulation of mICAM-1 expression
In a second set of experiments, knowing that IFN-γ could
mediate its effects via the JAK/STAT signalling pathway,
total and phosphorylated forms of STAT-1 were evaluated
using Western blotting. NHBE cells were cultured in
SABM and incubated with IFN-γ (1 ng/ml) for 24 h; fol-
lowed by infection with HRV-14 (TCID50 102.5) for speci-
fied short time points (0 min, 5 min, 10 min and 30 min)
to capture early initiation transcription events. NHBE cells
were then lysed at these short time points using a buffer
containing 1% Triton-X100, 20 mM Tris HCL (pH 8.0),
137 mM sodium chloride (NaCl), 10% glycerol, 1 mM
sodium orthovanadate, 2 mM EDTA, 1 mM phenylmeth-
ylsulfonyl fluoride (PMSF), 20 μM leupeptin and 0.15 U/
ml aprotinin. All reagents were molecular biology grade
(Sigma-Aldrich, UK). The cells were placed on ice for 20
min; total protein was collected by centrifugation and
assayed using a commercially available kit based on the
Lowry assay (Biorad, UK). 25 μg reduced protein samples
were electrophoresed on 12.5% SDS-PAGE and trans-
ferred to nitrocellulose membranes sandwiches (0.45 μm
pore size Novex, San Diego USA). Molecular weight mark-
ers were run with the samples. Membranes were blocked
with 10% w/v low-fat milk for 1 h in TBS-T and probed for
2 h with mouse anti-human anti-STAT-1 (Upstate Tech-
nology UK) diluted 1:1000 in TBS-T or mouse anti-
human anti-phosphoSTAT-1 (generous gift from R. A.
Knight, Imperial College, London). Membranes were
incubated with a horseradish peroxidase conjugated rab-
bit anti-mouse antibody (Dako, Denmark) diluted
1:20,000 in TBS-T for 1 h. The ECL system was used for
detection (Amersham, Buckinghamshire, UK). The mem-
branes were re-probed with a control mouse IgG as a neg-
ative control, and vinculin (Lab Vision, USA) as a control
for sample loading. The membranes were analysed densi-
tometrically (Model GS-670, BioRad, UK) using Molecu-
lar Analyst Software (version 1.5) (BioRad, UK) and
normalised against vinculin and expressed as a ratio to
total STAT-1.
To further support a key role for the JAK/STAT-1 pathway
in the regulation of ICAM-1 expression, the present
authors performed separate experiments incorporating
different concentrations of AG490 (Sigma-Aldrich, UK) to
inhibit JAK1/2. These experiments focused on examiningJournal of Inflammation 2008, 5:8 http://www.journal-inflammation.com/content/5/1/8
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the consequences of inhibiting JAK1/2 on ICAM-1 expres-
sion at the gene and protein level. To achieve this NHBE
cells were incubated with AG490 overnight and ICAM-1
expression analysed at 24 h post HRV-14 infection to cap-
ture the effects of AG490 on both m and s ICAM-1 expres-
sion. NHBE cells were incubated with AG490 at 20 μM, 40
μM, and 80 μM overnight at 37°C in humidified 5% CO2/
air; the cell monolayers were then washed and incubated
with IFN-γ conditioned media (1 ng/ml) or standard
SABM media for 24 h at 37°C in humidified 5% CO2/air.
After which, both the unconditioned and IFN-γ condi-
tioned media were removed; cell monolayers washed 3
times in PBS and then infected with SABM media contain-
ing HRV-14 (102.5TCID50/ml) or virus free media for 90
mins at 34°C, 5% CO2/air. At 24 h post HRV infection cell
monolayers were washed 3 times in PBS and cells were
collected via trypsinisation and centrifugation for
miCAM-1 protein analysis. 6 cytospins for each experi-
mental condition were prepared for immunofluorescence
performed as described above. For each experimental con-
dition, 500 cells from five random fields of view were
imaged and analysed for each experimental condition.
The data is expressed as the percentage of positive stained
cells ± S.E.M.
Inhibition of proteolytic cleavage of mICAM-1
As the down-regulation of membranous ICAM-1 was
accompanied by a simultaneous increase in the release of
sICAM-1 in response to both IFN-γ stimulation and infec-
tion with HRV-14, the present authors hypothesised that
proteolytic cleavage of mICAM-1 may, albeit partly, be
responsible for these observations. To test this hypothesis,
NHBE cells were treated with a broad spectrum protease
inhibitor cocktail containing serine, cysteine, metallopro-
tease and calpain inhibitors (Complete™ Boehringer
Ingelheim, Germany) at a concentration of 1 Complete™
mini tablet/10 ml media overnight. NHBE cells were then
stimulated with IFN-γ (1 ng/ml for 24 h) and infected
with HRV-14 (102.5TCID50/ml for 90 min). Levels of
membranous and soluble ICAM-1 levels were then deter-
mined at 0 h, 8 h, 24 h, and 96 h as described above.
Viral titre assay
The TCID50 method was used to calculate the concentra-
tion of the virus in cell culture supernatants at 0, 8, 24, 96,
120 and 144 h. Serial dilutions of cell culture superna-
tants were incubated in cell monolayers in 96 well plates
for 5 days at 34°C in humidified air containing 5%CO2.
The presence of cytopathic effect (CPE) in the wells was
used to calculate the TCID50 using the Karber formula [13-
15].
Statistical Methods
Means ± standard error (SE) were calculated, and statisti-
cally significant differences between experimental condi-
tions and controls were determined by repeated measure
Anova test at p < 0.05. We utilised the Tukey-Kramer HSD
test to perform post hoc comparisons between the mean
values of different epithelial cell treatments.
Results
Down-regulation of mICAM-1 expression: response to IFN-
γ and HRV infection
The present authors describe first the effects of the Th-1
mediator IFN-γ on expression behaviour of mICAM-1 iso-
form in NHBE cells, and how expression was altered in the
presence of HRV infection. Observed patterns of expres-
sion were consistent across the different source NHBE cul-
tures. mICAM-1 protein did not change in control
untreated, uninfected cells throughout the test 96 h cul-
ture period (Fig. 1A). HRV infection alone induced signif-
icantly mICAM-1 expression, peaking at 8 h and 24 h with
HRV-14 and HRV-1b respectively (**p = 0.02) compared
to control untreated uninfected cells), and remained ele-
vated to the end of the culture period. Cell-precondition-
ing with IFN-γ (1 ng/ml) in both uninfected and infected
cells also enhanced mICAM-1 expression at 0 and 8 h (*p
< 0.05 compared to untreated uninfected cells). Upregula-
tion of mICAM-1 was sustained in IFN-γ treated unin-
fected cells and IFN-γ treated cells infected with HRV-1b
(minor group rhinovirus) over 96 h. However, in IFN-γ
treated HRV-14-infected equivalent cells, levels of
mICAM-1 progressively fell to basal levels by 96 h (*p <
0.02 compared to IFN-γ treated uninfected cells and IFN-
γ treated HRV-1b infected cells). Trypan blue exclusion
assays demonstrated that IFN-γ and HRV infection had no
significant effect on cell viability (data not shown).
A similar pattern of expression was observed at the level of
mRNA. Increased mICAM-1 mRNA levels were observed
in IFN-γ pretreated uninfected cells and IFN-γ-naive HRV-
1b and HRV-14 infected at 24 and 96 h (Fig. 1B, *p =
0.01) compared to untreated uninfected cells). Levels of
mICAM-1 mRNA were also up-regulated in IFN-γ treated
HRV-1b infected cells (*p < 0.05, compared to untreated
uninfected cells). In contrast, mICAM-1 mRNA levels in
IFN-γ treated HRV-14 infected cells were significantly
down-regulated at 24 h (*p < 0.05 compared to IFN-γ
treated uninfected cells, untreated HRV-14 infected cells
and untreated HRV-1b), returning to near-basal levels by
96 h (*p < 0.05 compared to IFN-γ treated uninfected
cells, untreated HRV-14 infected cells and untreated HRV-
1b).
Minor group HRV-1b was used in control experiments to
examine whether the observed reduction in mICAM-1 in
response to IFN-γ and HRV-14 was receptor restricted as
HRV-1b is known to utilise a different receptor. Even
though HRV-1b induced mICAM-1 expression, it did not
have the same down-regulatory effect on mICAM-1 in theJournal of Inflammation 2008, 5:8 http://www.journal-inflammation.com/content/5/1/8
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Effect of IFN-γ cell preconditioning (1 ng/ml for 24 h) singly and with HRV-14 or HRV-1b infection (TCID50 102.5 for 90 mins)  on mICAM-1 protein expression (A) and mICAM-1 gene expression (B) in NHBE cells over the study period (0–96 h; 0 h rep- resenting the point immediately after 90 min inoculation period) Figure 1
Effect of IFN-γ cell preconditioning (1 ng/ml for 24 h) singly and with HRV-14 or HRV-1b infection (TCID50 102.5 
for 90 mins) on mICAM-1 protein expression (A) and mICAM-1 gene expression (B) in NHBE cells over the 
study period (0–96 h; 0 h representing the point immediately after 90 min inoculation period). mICAM-1 protein 
expression was measured using immunofluorescence. Data are mean ± S.E. of three separate experiments (Fig. 1A, *p < 0.05, 
IFN-γ treated uninfected and infected cells compared to control untreated and uninfected cells, **p = 0.02, IFN-γ treated HRV-
14 infected cells compared to IFN-γ treated uninfected cells and IFN-γ treated HRV-1b infected cells). Gene expression of 
mICAM-1 was semi-quantified using RT-PCR and densitometry and expressed as a ratio to the housekeeping gene, G3PDH. 
Data are mean ± S.E. of three separate experiments (Fig. 1B, *p < 0.05, IFN-γ treated infected cells compared to IFN-γ treated 
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presence of IFN-γ as HRV-14. Therefore subsequent exper-
iments focussed on the investigation of the molecular
mechanisms responsible for differential regulation of
ICAM-1 receptors in response to IFN-γ in response to
major group HRV infection only.
Inhibition of de novo protein synthesis and gene 
transcription
To examine at which level IFN-γ regulated expression of
ICAM-1 in uninfected and HRV-14 infected NHBE cells,
we first used two different pharmacological inhibitors,
cycloheximide and actinomycin D to block de novo pro-
tein synthesis and gene transcription respectively.
Cycloheximide treatment (10 μg/ml) of NHBE cells
induced a down-regulation of mICAM-1 protein expres-
sion irrespective of the presence of IFN-γ and HRV infec-
tion up to 24 h (*p < 0.05, Fig 2A). This reduced
expression continued up to 96 h in uninfected cells (*p <
0.05, Fig 2A). Similar pattern effects on mICAM-1 gene
transcription were observed in equivalent NHBE cell cul-
tures pretreated with actinomycin D (10 μg/ml) (Fig 2B).
The present authors postulate that the failure of cyclohex-
imde and actinomycin D to cause a complete abrogation
of mICAM-1 expression may be due to co-existence of
other mechanisms mobilising existent intracellular ICAM-
1 stores.
STAT-1 activation is decreased in HRV-infected cells
Following on above findings, the authors sought to
explore whether observed effects in IFN-γ-biased NHBE
cells on mICAM-1 levels during HRV-14 infection could
be mediated via a JAK/STAT signalling pathway; STAT-1
being a well-known signal transducer activated by IFN-γ.
As expected, in uninfected cells, IFN-γ induced a strong
band corresponding to phosphorylated STAT 1, approxi-
mately 90 KDa in size at all experimental time points (0–
90 mins) (Fig. 3A and 3B). However, in HRV-14 infected
cells, IFN-γ induction of phosphorylated STAT-1 was
weaker at 30 and 60 mins (Fig. 3B, **p < 0.04), which
appeared to correspond to the previously observed reduc-
tion in mICAM-1 expression (Fig 1). Next, to confirm the
important function of JAK/STAT-1 signalling in the induc-
tion of mICAM-1, uninfected and HRV-14 infected cells
were pre-treated with a range of concentrations of the
JAK2 inhibitor, AG490. As shown in Fig 4, IFN-γ mediated
induction of mICAM-1 levels was inhibited in the pres-
ence of AG490 in uninfected cells, at all three concentra-
tions used. However the authors failed to observe similar
inhibition with AG490 in HRV-infected cells (data not
shown). AG490 had no significant effect on epithelial cell
viability as assessed with trypan blue exclusion (cell via-
bility 97 ± 2.2%).
Increase in sICAM-1 release by IFN-γ and HRV-14 infection
In this present study, the simultaneous effect of IFN-γ on
the soluble ICAM receptor was also explored to determine
patterns of mICAM: sICAM-1 isoform differential process-
ing in uninfected and infected NHBE cells under same test
conditions. As previously reported by the authors [2],
sICAM-1 protein was undetected in untreated HRV-14
infected cell cultures at any time point. IFN-γ induced a
small but significant increase in sICAM-1 release in unin-
fected cells and cells infected with the minor group rhino-
virus, HRV-1b (Fig. 5A *p < 0.05 IFN-γ treated uninfected
and IFN-γ treated HRV-1b infected cells versus control
untreated uninfected cells). In contrast, when equivalent
IFN-γ treated cells were infected with HRV-14, sICAM-1
release is up-regulated in a time- dependent fashion from
0 to 96 h (*p < 0.05, Fig. 5A), with levels reaching a 20-
fold increase over IFN-γ stimulated uninfected NHBE cells
and controls (**p < 0.03, Fig. 5A) at 96 h.
IFN-γ had no significant effect on sICAM-1 gene expres-
sion in both uninfected and HRV-infected NHBE cells (Fig
5B), suggesting that sICAM-1 release may be regulated at
a transcriptional level. Accordingly, separate experiments
investigated effects of cycloheximide and actinomycin D
on sICAM-1 release. Irrespective of the presence of infec-
tion, cycloheximide inhibited sICAM-1 release from IFN-
γ stimulated uninfected and infected NHBE cells at 24 h
(*p < 0.05, Fig 6A), whilst producing a significant reduc-
tion at 96h (*p < 0.05, Fig 6A). Trypan blue exclusion
assay demonstrated that cycloheximide had no significant
effect of cell viability (95 ± 2.1%). Actinomycin D abol-
ished sICAM-1 release only at the 96 h time point (Fig
6B). Actinomycin D did not have a detrimental effect on
cell viability (96 ± 1.8%).
Role of proteolysis in sICAM-1 production
As the sICAM-1 mRNA transcript failed to increase in
response to IFN-γ and HRV infection, it followed that
ICAM-1 gene splicing was not the primary mechanism
underlying sICAM-1 release in equivalent conditions.
Equally, observed soluble receptor secretion was associ-
ated with simultaneous down-regulation of the mICAM-1
form in IFN-γ-biased NHBE cells during HRV-14 infec-
tion; the present authors postulated that sICAM-1 release
under these conditions could likely be secondary to prote-
olytic cleavage of the membrane-bound form. Presence of
this mechanism was shown in separate experiments incor-
porating broad spectrum protease inhibitors which
blocked mICAM-1 cleavage, demonstrating a reduction in
sICAM-1 release in IFN-γ treated uninfected and HRV-
infected cells throughout the experimental time period
(Fig 7A *p < 0.01,**p < 0.05, protease treated versus
untreated cells); whilst mICAM-1 expression in equivalent
IFN-γ treated uninfected and HRV-infected cells remainedJournal of Inflammation 2008, 5:8 http://www.journal-inflammation.com/content/5/1/8
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Effect of cycloheximide (fig 2A, 10 μg/ml for 2 h) and actinomycin D (Fig 2B, 10 μg/ml for 2 h) on mICAM-1 surface expression  in IFN-γ treated uninfected and HRV-14 infected cells Figure 2
Effect of cycloheximide (fig 2A, 10 μg/ml for 2 h) and actinomycin D (Fig 2B, 10 μg/ml for 2 h) on mICAM-1 sur-
face expression in IFN-γ treated uninfected and HRV-14 infected cells. Data are mean ± S.E. of three separate exper-
iments (Fig. 2A, *p < 0.05, cycloheximide treated cells compared with equivalent un-treated cells, **p < 0.05, IFN-γ treated 
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Effect of HRV-14 on STAT-1 levels in NHBE cells at 0–90 min of infection with HRV-14 (TCID50 102.5) Figure 3
Effect of HRV-14 on STAT-1 levels in NHBE cells at 0–90 min of infection with HRV-14 (TCID50 102.5). Phospho-
rylated STAT-1 was analysed using Western blotting. Fig. 3A is a representative blot illustrating phosphorylated STAT-1 (90 
KDa) levels at 15 and 30 min of infection. Vinculin was analysed using Western blotting as a control for sample loading. West-
ern blots from three separate experiments were analysed densitometrically (Fig. 3B) normalised against vinculin and expressed 
as a ratio to total STAT-1. Data are mean ± S.E. (*p < 0.05 compared to IFN-γ treated uninfected cells at equivalent time points 
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elevated at all time points (Fig 7B *p < 0.05 protease
treated versus untreated cells).
Consequent effects on viral titres
To relate above observations on mICAM: sICAM-1 iso-
form differential processing in the context of IFN-γ effects
and consequence on cell infectivity, viral titres were per-
formed on appropriate test cultures. A steep increase in
viral titres was observed in untreated HRV-infected NHBE
cells at 8 h, remaining elevated thereafter. In contrast, IFN-
γ preconditioning of cells followed by HRV-14 infection
induced a down-regulation in viral titres at 8 h compared
to untreated infected cells and HRV-1b infected cells (*p
= 0.05, Fig. 8). At 24 and 96 h, there were no significant
differences in recovered viral titres from infected cell cul-
tures irrespective of IFN-γ pre-treatment. Significantly,
viral titres from HRV-1b infected cells were less than those
observed from HRV-14 infected cells at 8 and 24 h (†p <
0.05 compared to HRV-14 infected cells). To investigate
whether local changes in the mICAM-1: sICAM-1 levels
could influence epithelial cell infectivity, experiments
were extended to examine viral titres at 120 and 144 h.
Interestingly, notable differences were observed at these
later time points; specifically viral titres from IFN-γ treated
HRV-14 infected NHBE cells were greatly reduced com-
pared to untreated HRV-infected NHBE cells and
untreated and treated HRV-1b infected cells (‡p < 0.05,
Fig. 8).
All the above experiments were repeated using NHBE cells
from two further sources; apart from differences in
response magnitude, the pattern of data was similar.
Discussion
The present authors describe for the first time that IFN-γ
can exert a simultaneous differential effect on both forms
of the rhinovirus receptor, ICAM-1, in target infected cells.
Specifically, the membranous form of ICAM-1 is down-
regulated in IFN-γ-biased epithelial cells exposed to the
major group rhinovirus, HRV-14, whilst sICAM-1 release
is enhanced.
The current experiments demonstrate that mICAM-1
expression is induced by both major and minor group rhi-
noviruses. Since both group viruses utilise distinct cellular
receptors [21], the observed induction in mICAM-1
expression appears to be not receptor restricted. However,
when NHBE cells are first pre-conditioned with IFN-γ and
subsequently infected, seminal different response patterns
are observed between major and minor group rhinovi-
ruses. Expression of mICAM-1 is down-regulated within
24 h in IFN-γ-biased HRV-14-infected cells, whilst
mICAM-1 levels remain elevated in equivalent mediator
conditioned cells infected with the minor group serotype.
It follows that the effects of IFN-γ and major group rhino-
virus together are likely to be receptor mediated. These
data support previous findings by Sethi et al (1997) who
demonstrated a reduction in mICAM-1 expression in
response to IFN-γ and HRV-14 in separate cell lines.
Whilst these observations require to be confirmed in vivo,
there are potential implications for the capability of IFN-γ
to modulate selectively HRV-14 cell receptor expression,
particularly as mICAM-1 is critical in both inflammatory
cell mobilisation and virus-host cell binding/internalisa-
tion. A down-regulation in mICAM-1 expression on the
epithelial cell surface may limit rhinovirus infection by
decreasing the number of receptors available for virus
binding; whilst possibly also reducing the magnitude of
subsequent effector response at the target site.
The current study next explored possible molecular mech-
anisms by which mICAM-1 down-regulation may occur in
IFN-γ-biased cells exposed to HRV-14. As IFN-γ-mediated
effects were observed to be sensitive, albeit not wholly, to
pharmacological inhibition with cycloheximide and
actinomycin D, the authors postulated that modulation of
ICAM-1 expression could at least be facilitated at the tran-
scriptional and translational level. There is abundant evi-
dence that STAT-1 signalling is a key regulatory pathway;
Effect of AG490 (20–80 μM) on mICAM-1 protein levels in  IFN-γ treated uninfected cells Figure 4
Effect of AG490 (20–80 μM) on mICAM-1 protein lev-
els in IFN-γ treated uninfected cells. mICAM-1 expres-
sion was evaluated using immunofluoresence. Data are mean 
± S.E. of three separate experiments (Fig. 4A, *p < 0.05, Cells 
treated with AG490 prior to stimulation with IFN-γ com-
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Effect of IFN-γ cell preconditioning (1 ng/ml for 24 h) singly and with HRV-14 or HRV-1b infection (TCID50 102.5 for 90 mins)  on sICAM-1 protein release (A) and sICAM-1 gene expression (B) in NHBE cells over the study period Figure 5
Effect of IFN-γ cell preconditioning (1 ng/ml for 24 h) singly and with HRV-14 or HRV-1b infection (TCID50 102.5 
for 90 mins) on sICAM-1 protein release (A) and sICAM-1 gene expression (B) in NHBE cells over the study 
period. sICAM-1 in cell culture supernatants was assayed using ELISA. Data are mean ± S.E. of three separate experiments (Fig 
5A,*p < 0.05, IFN-γ treated HRV-14 infected cells compared to IFN-γ treated uninfected cells and IFN-γ treated HRV-1b 
infected cells, **p = 0.02, IFN-γ treated infected cells compared to IFN-γ treated uninfected cells and IFN-γ treated HRV-1b 
infected cells). Gene expression of sICAM-1 was semi-quantified using RT-PCR and densitometry and expressed as a ratio to 
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Effect of cycloheximide (fig 6A, 10 μg/ml for 2 h) and actinomycin D (Fig 6B, 10 μg/ml for 2 h) on sICAM-1 expression in IFN-γ  treated uninfected and HRV-14 infected cells Figure 6
Effect of cycloheximide (fig 6A, 10 μg/ml for 2 h) and actinomycin D (Fig 6B, 10 μg/ml for 2 h) on sICAM-1 
expression in IFN-γ treated uninfected and HRV-14 infected cells. Data are mean ± S.E. of three separate experiments 
(Fig. 6A, *p < 0.05, cycloheximide treated cells compared with equivalent un-treated cells, **p < 0.05, IFN-γ treated uninfected 
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Effect of protease inhibitors on sICAM-1 release (A) and mICAM-1 levels (B) Figure 7
Effect of protease inhibitors on sICAM-1 release (A) and mICAM-1 levels (B). Cell cultures were pre-incubated with 
1 complete™ mini tablet/10 ml of media; sICAM-1 in associated supernatants was assayed using ELISA. Data are mean ± S.E. of 
three separate experiments (Fig. 7A, *p < 0.01, **p < 0.05, IFN-γ treated infected cells pre-incubated with protease inhibitors 
compared to equivalent untreated IFN-γ treated infected cells). mICAM-1 protein expression was measured using immunoflu-
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although not necessarily mediating all effects of IFN-γ
[18], it made sense to first determine whether STAT-1 reg-
ulation is involved in mICAM-1 modulation during HRV-
14 infection. The present data show that IFN-γ induces
phosphorylation of STAT-1; its effects on membranous
ICAM-1 levels are inhibited in a dose-dependent fashion
by AG490 in the absence of infection. These data suggest
that the selective transcriptional actions of IFN-γ are likely
to be mediated by a conventional JAK/STAT signal trans-
duction pathway, whether wholly or partly in uninfected
cells. Interestingly the present authors did not observe
AG490 inhibition on mICAM-1 protein levels in HRV-
infected cells. This may be due to the fact that this signal-
ling pathway is suppressed by HRV in infected cells. More-
over, the magnitude of STAT-1 phosphorylation was
lower after 30 mins, though not after 15 mins, treatment
in HRV-infected cells compared with uninfected equiva-
lents. The authors are aware of several reports on virus
interference with IFN-γ signalling. Respiratory viruses
such as Sendai, Cytomegalovirus, Adenovirus, Vaccinia,
simian virus 5, have been shown to reduce STAT phospho-
rylation [22-26]. It is possible that human rhinoviruses
may behave similarly. In addition, HRV proteins may
interfere directly with host JAK/STAT signalling mecha-
nism preventing interferon-induced transcriptional
responses. Several viruses have been demonstrated to
employ this mechanism [27-29]. It follows that STAT-1
phosphorylation may be inhibited by HRV without affect-
ing other molecules such as JAK involved in the signalling
cascade. However, whilst HRV-14 manipulation of inter-
feron-dependent immunity is possible, further explora-
tion of the interaction between HRV-14/IFN-γ/JAK/STAT
signalling is required to explain the observed lack of
AG490 inhibition on mICAM-1 levels in HRV-infected
cells; equally other signalling molecules may be operative.
The simultaneous effects of IFN-γ and rhinovirus infection
were also explored on the soluble form of ICAM receptor.
IFNγ induces a small but significant increase at 8–96 h in
sICAM-1 release from uninfected cells. In the presence of
major group rhinovirus, sICAM-1 release from IFN-γ-
biased cells is augmented in a time-dependent manner. In
contrast, infection with the minor group rhinovirus had
no significant effect on sICAM-1 release. The concurrent
enhanced sICAM-1 release and mICAM-1 downregulation
during HRV-14 infection could play a pivotal function in
limiting HRV-14 infection within a biased IFN-γ milieu.
The present authors postulate that this differential ICAM-
1 isoform processing may create an anti-viral influence by
reducing the density of the HRV docking target on the cell
surface, whilst the released soluble ICAM-1 molecules
serve as a decoy to prevent further HRV binding to epithe-
lial cells and infection by binding to virus particles.
Whilst HRV replication was not measured directly, the
present data demonstrate that changes in relative expres-
sion levels of membrane-bound and secreted ICAM-1
forms are followed by reduction in analysed HRV-14
titres. Viral levels were reduced in IFN-γ treated HRV-14
infected cells at 8 h compared to untreated HRV-14
infected cells. It is possible that the observed reduction in
viral titres at this time point reflects a direct effect of IFN-
γ on viral replication, although this is just hypothesis at
the moment. In addition, at 120 and 144 h post infection,
epithelial cell infectivity appeared to be reduced in IFN-γ
treated HRV-14 infected cells compared to untreated cells
infected with HRV-14 and both IFN-γ treated and
untreated HRV-1b infected cells. These observations are
consistent with previous studies which also demonstrated
reduced viral titres in IFN-γ treated and HRV-14 infected
H292 cells [14]. Since these observations appear to be spe-
cific to the major group rhinovirus that utilise ICAM-1 as
its cellular receptor, the decrease in viral titres are likely to
be a consequence of IFN-γ on differential modulation of
the ICAM-1 variants. Whilst it is possible that the
observed later effects on viral titres may be secondary to de
novo IFN-γ production inhibiting viral replication, in our
previous studies we did not observe increasing IFN-γ lev-
els over the experimental period. The relevance of defense
mechanisms driven by IFN-γ-induced processing of the
Effect of IFN-γ cell preconditioning (1 ng/ml for 24 h) on viral  titres (0–144 h) Figure 8
Effect of IFN-γ cell preconditioning (1 ng/ml for 24 h) 
on viral titres (0–144 h). Viral titres in cell culture super-
natants were assayed using TCID50 method. Data are mean ± 
S.E. of three separate experiments (Fig. 8, *p < 0.05, HRV-
infected cells at 0 h compared HRV-infected cells at 8 h, ‡p < 
0.05, IFN-γ treated HRV-14 infected cells compared to un-
treated HRV-14 infected cells and IFN-γ treated HRV-1b 
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HRV-14 receptor for host epithelial cell infectivity remains
to be clarified in future studies.
The current investigation conducted preliminary experi-
ments to explain possible source/s for the enhanced solu-
ble isoforms. The underlying mechanisms responsible for
IFN-γ induced modulation of sICAM-1 levels during HRV
infection include alternative splicing of the ICAM-1 gene
and proteolytic cleavage of the membranous form. Alter-
native splice donor site selection results in a reading
frameshift of the ICAM-1 gene with elimination of the
transmembrane and cytoplasmic domains [19]. However,
the present authors concluded that gene splicing is not the
predominant mechanism driving sICAM-1 release as
mRNA transcript expression is not induced by IFN-γ and
HRV-14, suggesting other mechanisms are operative.
However, Actinomycin D dramatically reduced sICAM-1
release suggesting that gene transcription is involved in
the regulation of ICAM-1 receptors in bronchial epithelial
cells, albeit not transcription of the actual ICAM-1 gene;
possibly the transcription of a gene regulating proteolysis
such as MMPs or inhibitors of these proteases. Indeed,
separate experiments showed proteolytic cleavage of
mICAM-1 as potentially pivotal to sICAM-1 release. Cer-
tainly, IFN-γ and HRV-14 together appear to induce an
increase in sICAM-1 release, whilst decreasing mICAM-1
expression on the epithelial cell surface. Protease inhibi-
tors with a broad spectrum of activity had no effect on
mICAM-1 expression in IFN-γ-stimulated uninfected
NHBE cells. However, there was near-complete abroga-
tion of sICAM-1 release from both IFN-γ uninfected and
HRV-infected cells incubated with same protease inhibi-
tors. It is thus plausible that during HRV infection, IFN-γ
promotes the enzymatic cleavage of mICAM-1 resulting in
a downregulation of cell surface mICAM-1, with simulta-
neous enhanced release of sICAM-1 into the local extracel-
lular environment. Furthermore, the involvement and
regulation of selective proteolytic enzymes such as MMPs
and caspases in the cleavage of mICAM-1 should also be
considered and addressed in future studies, especially in
the context of human airway HRV infection. Indeed,
keratinocyte and astrocyte models have demonstrated
that the sICAM-1 release mechanism is sensitive to metal-
loproteinase (MMP) inhibitors [9,30] suggesting a critical
role for MMPs in the production of sICAM-1. Interest-
ingly, in addition to establishing the role of proteases in
the production of sICAM-1, the authors demonstrated the
JAK/STAT signalling pathway as a potential mechanism in
the regulation of ICAM-1 receptors. The cellular response
to virus infection is complex and is likely to involve mul-
tiple genes, therefore as the JAK/STAT pathway is a generic
signalling mechanism, it may be implicated in the activa-
tion of accessory genes, such as proteases/protease inhib-
itors involved in the regulation of ICAM-1 expression as
opposed to the ICAM-1 gene itself.
In conclusion, this current study highlights an interesting
modulation of ICAM-1 receptor isoforms by the Th-1
mediator, IFN-γ in the presence of HRV-14 infection.
Whilst some findings are preliminary, the present in vitro
cell model observations are in line with previous data
from human experimental rhinovirus studies. Winther et
al, 2002 [31], demonstrated that nasal epithelial cell
mICAM-1 expression is upregulated within 24 h of HRV
inoculation, decreasing rapidly to baseline by day 9; with
simultaneous increase in sICAM-1 release into nasal lav-
age, albeit that significance was only noted on day 3. Sep-
arate studies by Hildebrandt et al (1996) [32] also
detected enhanced soluble receptor levels during the acute
phase of naturally acquired upper respiratory tract infec-
tions. These observations need to be pooled together to
design future experiments to determine the relevance of
differential ICAM-1 processing on natural rhinovirus
infection; this could unravel key molecular targets for
anti-HRV pharmacological engineering.
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